While ICAM-1-mediated endo- and transcytosis of drugs is suitable for cancer treatment, we aimed to generate ICAM-1-specific nanobodies that remain bound to the epithelial cell surface in order to immobilize captured allergens and prevent their uptake through the mucosal barrier. Here, ICAM1 is linked to cancer.